中国医药：注射用头孢西丁钠通过仿制药一致性评价

Core Viewpoint - China Medical (600056) announced that its wholly-owned subsidiary, Sanyo Pharmaceutical, received approval from the National Medical Products Administration for two supplemental applications for injectable Cefazolin Sodium, which passed the consistency evaluation of generic drug quality and efficacy [1] Group 1 - The approved drug had a sales revenue of approximately 1.611 billion yuan in domestic public hospitals and grassroots medical terminals in 2023 [1] - The company has not made any sales of this drug in 2023 [1]